Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2013

View Archived Issues

The identification of a novel target for the treatment of obesity-related endothelial dysfunction

Addex shows preclinical proof of concept for ADX-71441 in Charcot-Marie-Tooth 1A disease

New proteins binding to human ubiquitin designed by Scil Proteins

New gene therapy vectors for adrenoleukodystrophy

Autifony Therapeutics synthesizes new voltage-gated potassium channel modulators

Stemline's SL-401 produces complete response in BPDCN

Novel NS3/NS4A inhibitors disclosed by Bristol-Myers Squibb

Rib-X Pharmaceuticals synthesizes new antibacterial agents

Researchers at CSL disclose new G-CSF-R antibodies

HOXC10 gene implicated in response to breast cancer chemotherapy

AstraZeneca synthesizes promising DGAT1 inhibitor

ChemoCentryx's CCR9 inhibitor CCX-507 enters clinical trials

Orexigen Therapeutics progresses with FDA on resubmission of Contrave NDA

FDA grants orphan drug status to novel terlipressin formulation for treatment of ascites

XOMA reports topline data from study of gevokizumab in acne vulgaris

Pivotal ESTEEM trials of apremilast in psoriasis meet key endpoints

Gliadel Implant launched in Japan

Alkermes reports topline results from phase I study of novel combination treatment for schizophrenia

Vaccinex begins phase I trial of VX-15/2503 in multiple sclerosis

Study identifies gene linked to breast cancer liver metastases

European Commission approves expanded indication for Prevenar 13 vaccine

Merus selects lead candidate for AML

Ariad and U.K.'s NCRI to collaborate on phase III ponatinib trial

Galapagos delivers fifth drug candidate to GSK under disease-modifying drug alliance

Krystexxa approved in E.U. for certain patients with chronic tophaceous gout

GVHD studied in canine model of in utero hematopoietic cell transplantation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...